Applied DNA Sciences, Inc. to Present at The MicroCap Conference on April 4th in New York City at the Essex House

March 16, 2017 3:35 PM

NEW YORK, NY / ACCESSWIRE / March 16, 2017 / Applied DNA Sciences, Inc. (NASDAQ: APDN) will be presenting at this year's The MicroCap Conference on April 4th in New York City, sponsored by The Special Equities Group and Maxim Group. CONFERENCE OVERVIEW AND STRUCTURE The MicroCap Conference is an exclusive event for investors who specialize in small and microcap stocks. It is an opportunity to be introduced to and speak with management at...

Read more

Mount TAM Biotechnologies, Inc. to Present at The MicroCap Conference on April 4th in New York City at the Essex House

March 16, 2017 3:29 PM

NEW YORK, NY / ACCESSWIRE / March 16, 2017 / Mount TAM Biotechnologies, Inc. (OTC PINK: MNTM) will be presenting at this year's The MicroCap Conference on April 4th in New York City, sponsored by The Special Equities Group and Maxim Group. CONFERENCE OVERVIEW AND STRUCTURE The MicroCap Conference is an exclusive event for investors who specialize in small and microcap stocks. It is an opportunity to be introduced to and speak with management...

Read more

Abattis Team Positions for Next Stage of Growth

March 13, 2017 9:19 AM

VANCOUVER, BC / ACCESSWIRE / March 13, 2017 / Abattis Bioceuticals Corp. (OTCQB: ATTBF) (CSE: ATT) (the "Company" or "Abattis") is pleased to announce the addition of Jaclyn Thomson, PhD, to our senior management team at Northern Vine Labs, and the appointment of Rene David to the Abattis Board of Directors. As the construction and buildout of Northern Vine Labs continues, more key management hires and appointments will accompany this next stage...

Read more

Cell MedX Corp. Announces First Subjects Screened and Qualified for the Observational Clinical Trial

March 9, 2017 8:09 AM

CARSON CITY, NV / ACCESSWIRE / March 9, 2017 / Cell MedX Corp. (OTCQB: CMXC), ("Cell MedX" or the "Company"), is pleased to announce that Dr. Richard Tytus, the Lead Investigator on the previously announced Observational Clinical Trial (the "Trial"), and his team at Hamilton Medical Research Group have commenced screening for qualified subjects. The group of seven potential study participants have been screened with an additional five subjects...

Read more

InMed Pharmaceuticals to Present at the 29th Annual ROTH Conference

March 8, 2017 8:00 AM

VANCOUVER, BC / ACCESSWIRE / March 8, 2017 / InMed Pharmaceuticals, Inc. ("InMed") (CSE: IN; OTCQB: IMLFF) announces today that Eric A. Adams, Chief Executive Officer, will be presenting to U.S. institutional investors at the 29th Annual ROTH Conference, which is being held March 12-15, 2017, at the Ritz Carlton, Laguna Niguel, California. "The ROTH Conference is one of the largest in the nation, and it does a wonderful job introducing small...

Read more

Biotech Products Services and Research Inc. to Pursue Medical Cannabis License in Florida

March 2, 2017 4:00 PM

MIAMI, FL / ACCESSWIRE / March 2, 2017 / Biotech Products Services and Research Inc. (OTC PINK: BPSR) ("BPSR" or the "Company") recently announced in a Form 8-K that it has entered into an agreement pursuant to which the Company intends to aggressively pursue obtaining the required license to operate within the medical cannabis industry in the state of Florida upon the Florida legislature's finalization of the plans for implementing the recently...

Read more

InMed Pharmaceuticals Files PCT Patent for Epidermolysis Bullosa Simplex

March 2, 2017 8:30 AM

VANCOUVER, BC / ACCESSWIRE / March 2, 2017 / InMed Pharmaceuticals, Inc. ("InMed") (CNSX: IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, today announced the filing of an international Patent Cooperation Treaty (PCT) application, an important component in providing intellectual and commercial protection for INM-750 as a cannabinoid-based topical therapy for...

Read more

INmune Bio Co-Founder, Professor Mark Lowdell, Named One of Europe's Academic-Entrepreneur Superstars

March 2, 2017 8:30 AM

LA JOLLA, CA / ACCESSWIRE / March 2, 2017 / INmune Bio, Inc., a cancer immunotherapy company focused on developing therapies that prime natural killer (NK) cells to attack cancer, today announces that its co-founder, Professor Mark Lowdell, PhD, FRCPath FRSB, has been named one of Europe's 10 academic-entrepreneur superstars by Labiotech, the leading digital media covering the European Biotech industry. "I was surprised and delighted to be...

Read more

Abattis Completes Audit and Prepares to Launch Northern Vine Labs

February 24, 2017 5:59 PM

VANCOUVER, BC / ACCESSWIRE / February 24, 2017 / Abattis Bioceuticals Corp. (OTCQB: ATTBF) (CNSX: ATT) ("ATT" or the "Company") is pleased to announce the completion of their annual audit. The delay in filing was due to an eventful year with new programs coming online and an aggressive strategy to cut non-core assets resulting in prolonged consolidations and subsequent review. Management has been focusing their efforts on their Northern Vine...

Read more

Cell MedX Corp. Engages Think Ink Marketing

February 24, 2017 5:00 PM

CARSON CITY, NV / ACCESSWIRE / February 24, 2017 / Cell MedX Corp. (OTCQB: CMXC) ("Cell MedX" or the "Company"), an early development stage bio-tech company focusing on the discovery, development, and commercialization of therapeutic and non-therapeutic products that promote general wellness, announced today that it has retained Think Ink Marketing Data & Email Services, Inc. ("Think Ink") to develop an investor outreach program. The Company...

Read more

District Court Grants MorphoSys's Request to Add Second Patent in Lawsuit with Janssen Biotech and Genmab

February 15, 2017 2:00 AM

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / February 15, 2017 / MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC PINK: MPSYY) today announced that it has added a second patent with US Patent Number 9,200,061 to its lawsuit against Janssen Biotech, and Genmab, A/S. This patent claims methods of treating hematologic cancer associated with the undesired presence of CD38-positive cells by administering antibodies that bind to a specific region...

Read more

Biotech Products Services and Research, Inc. Commences Shipments of Company's First Amniotic Allograft Product

February 14, 2017 4:00 PM

MIAMI, FL / ACCESSWIRE / February 14 , 2017 / Biotech Products Services and Research, Inc. (OTC PINK: BPSR) ("Company") today announced that its wholly-owned subsidiary, Anu Life Sciences Inc. ("Anu"), has recently received satisfactory validation for its first production batch of amniotic allograft biological product ("New Amnio Product") and has commenced shipping the New Amnio Product to customers. The New Amnio Product is being sold through...

Read more

Abattis Bioceuticals Corp. Announces Postponement of its Annual General Meeting

February 14, 2017 3:07 PM

VANCOUVER, BC / ACCESSWIRE / February 14, 2017 / Abattis Bioceuticals Corp. (OTCQB: ATTBF) (CSE: ATT) (the "Company") is announcing today that it will be seeking to adjourn its upcoming annual general meeting of shareholders, originally scheduled to be held on Friday, February 17, 2017, at 10:00 a.m. (Vancouver time) (the "Meeting"), to a to-be-announced date. The Company will seek to hold the adjourned meeting as soon as practicable. As of this...

Read more

MorphoSys to Present at Upcoming Conference

February 10, 2017 5:30 AM

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / February 10, 2017 / MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) will present at the following conference: LEERINK Partners 6th Annual Global Healthcare Conference Date: February 16, 2017, 3:30 pm EST (9:30 pm CET, 8:30 pm GMT) Venue: New York, USA Presenter: Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG A PDF version of the presentation will be provided at...

Read more

Cellectar Biosciences to Present at the 2nd Annual Disruptive Growth & Healthcare Conference

February 9, 2017 8:30 AM

NEW YORK, NY / ACCESSWIRE / February 9, 2017 / Cellectar Biosciences (NASDAQ: CLRB), an oncology-focused, clinical stage biotechnology company, announces today that it will be presenting at the 2nd Annual Disruptive Growth & Healthcare Conference on Thursday, February 16 at 8:30 AM EST in the Tribeca Room of Convene Conference Center, 730 Third Avenue in New York City. The 2017 Disruptive Growth & Healthcare Conference will offer the...

Read more

CVR Medical Announces Increase to Previously Announced Financing

February 7, 2017 3:51 PM

VANCOUVER, BC / ACCESSWIRE / February 7, 2017 / CVR Medical Corp. (TSX-V: CVM) (FSE: B3BN) (OTCQB: CRRVF) ("CVR Medical" or the "Company") is pleased to announce that, due to strong demand, the Company has increased the size of its previously announced private placement financing to 7.58 million units (the "Units"), at a price of $0.33 per unit, for aggregate gross proceeds to the Company of approximately $2.5 million (the "Financing"). Each...

Read more

CVR Medical Retains DuVal & Associates to Navigate FDA Process

February 6, 2017 8:57 AM

VANCOUVER, BC / ACCESSWIRE / February 6, 2017 / CVR Medical Corp. (TSX-V: CVM) (FSE: B3BN) (OTCQB: CRRVF) ("CVR Medical") has retained the services of DuVal & Associates, P.A., a Minneapolis-based, regulatory law firm focused on counsel within the medical device and pharmaceutical industries. In addition to its strategic advisory role, DuVal & Associates will represent CVR throughout the process of FDA approvals and clearances for its...

Read more

Abattis Audit Update

February 3, 2017 4:05 PM

VANCOUVER, BC / ACCESSWIRE / February 3, 2017 / Abattis Bioceuticals Corp. (OTCQB: ATTBF) (CSE: ATT) ("ATT" or the "Company") announces that it is completing work on its audit and has been working with its auditor to complete the process in order to have it ready to file as soon as possible. It is anticipated that this delay will result in a temporary issuer cease trade order, which Abattis shall seek to remove as soon as the audited financial...

Read more

IsoRay, Inc. to Present at the 2nd Annual Disruptive Growth & Healthcare Conference

February 2, 2017 9:25 AM

NEW YORK, NY / ACCESSWIRE / February 2, 2017 / IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck, and gynecological cancers, announced today that it will be presenting at the 2nd annual Disruptive Growth & Healthcare Conference on Wednesday, February 15, 2017 at 12:45 PM EST. Tom LaVoy, Chairman and...

Read more

Arch Therapeutics to Present at Source Capital Group's 2017 Disruptive Growth & Healthcare Conference

January 13, 2017 2:01 PM

WESTPORT, CT / ACCESSWIRE / January 13, 2017 / Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostatic Device™ (AC5™) for use in controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, will present at the Source Capital Group's 2017 Disruptive Growth & Healthcare Conference. Chief Executive Officer Terrence W. Norchi, MD will...

Read more